Insight Molecular Diagnostics (IMDX) Depreciation & Amortization (CF) (2015 - 2026)

Insight Molecular Diagnostics has disclosed Depreciation & Amortization (CF) across 12 years of filings, most recently posting $631000.0 for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $631000.0, up 28.51% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.4 million (up 41.48% YoY), and the FY2025 annual result was $2.2 million, up 46.67% from the prior year.
• Depreciation & Amortization (CF) came in at $631000.0 for Q1 2026 at Insight Molecular Diagnostics, up from $600000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $631000.0 in Q1 2026 to a low of $287000.0 in Q1 2022.
• The 5-year median for Depreciation & Amortization (CF) is $404000.0 (2023), against an average of $436882.4.
• Across the five-year window, Depreciation & Amortization (CF) jumped 137.19% in 2022 and slumped 30.44% in 2024, its largest moves.
• Insight Molecular Diagnostics' Depreciation & Amortization (CF) stood at $400000.0 in 2022, then declined by 22.25% to $311000.0 in 2023, then soared by 81.67% to $565000.0 in 2024, then climbed by 6.19% to $600000.0 in 2025, then gained by 5.17% to $631000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $631000.0 (Q1 2026), $600000.0 (Q4 2025), and $584000.0 (Q3 2025), per Business Quant data.